ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

encequidar

Also written as “HM30181AK tablet + Irinotecan tablets”, “Oral Paclitaxel in combination with Encequidar tablet” and “Encequidar tablet”.

Its studies are mostly in Breast Neoplasms, led by 2 companies.

Drug pageHm-30181: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 6, 20096 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceuticalits history only40 open or runningphase 1since Aug 6, 2009Aug 6, 2009none ahead
Health Hope Pharma22 open or runningphase 3since Feb 14, 2025Feb 14, 2025Dec 2026phase 1 · NCT07580833

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Health Hope Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named encequidarINNProposed as its International Nonproprietary Name in WHO's List 119
  2. Feb 14, 2025First study: phase 3 study in Breast NeoplasmsFirst studyNCT06835400 · 340 planned
  3. Mar 24, 2026Phase 1 study in Breast NeoplasmsNCT07580833 · 46 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in Breast NeoplasmsNCT07580833
  2. Apr 2028Primary completion: phase 3 study in Breast NeoplasmsNCT06835400

TargetBeta

ABCB1 →read by rule
“P-glycoprotein 1 inhibitor”ChEMBL 37, by rule

Studies

All 2 Health Hope Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07580833Breast Neoplasms1Not yet recruitingDec 202646
NCT06835400Breast Neoplasms3Not yet recruitingApr 2028340

How it is read

Names in the registry

  • “HM30181AK tablet + Irinotecan tablets”, 2 entries
  • “Oral Paclitaxel in combination with Encequidar tablet”, 1 entry
  • “Encequidar tablet”, 1 entry
  • “Paclitaxel+HM30181”, 1 entry
  • “HM30181AK 1mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.